Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Price, Quote & AI Analysis
Live SGMT stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Sagimet Biosciences Inc. Series A Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for Sagimet Biosciences Inc. Series A Common Stock (SGMT), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Sagimet Biosciences Inc. Series A Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Sagimet Biosciences Inc. Series A Common Stock Overview
Company information
Company Overview
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Company Details
Technical Indicators
Key technical analysis metrics and signals
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Sagimet Biosciences Inc. Series A Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...